CLINICAL TRIALS PROFILE FOR PF-06700841
✉ Email this page to a colleague
Clinical Trials for PF-06700841
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02310750 ↗ | A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation | Completed | Pfizer | Phase 1 | The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms). |
NCT02958865 ↗ | Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis | Completed | Pfizer | Phase 2 | The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis. |
NCT02969018 ↗ | Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis | Completed | Pfizer | Phase 2 | The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis. |
NCT02974868 ↗ | Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata | Completed | Pfizer | Phase 2 | This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks. This includes an up to 5 weeks Screening Period, a 24 week Treatment Period, a 4 week Drug Holiday (#1), an up to 12 month Single Blind (investigator open, sponsor open and subject blind) Extension Period, a 4 week drug holiday (#2), a 6 month Cross Over Open Label Extension Period and a 4 week Follow up Period. |
NCT03236493 ↗ | Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers | Completed | Pfizer | Phase 1 | This study is a phase 1 study of PF-06700841. PF-06700841 is being developed for treatment of inflammatory bowel disease. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06700841 after multiple oral doses of PF-06700841 in Japanese healthy volunteers. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for PF-06700841
Condition Name
Clinical Trial Locations for PF-06700841
Trials by Country
Clinical Trial Progress for PF-06700841
Clinical Trial Phase
Clinical Trial Sponsors for PF-06700841
Sponsor Name